而且,今年1月Dupixent被FDA批准扩大适应症人群,用于1-11岁、体重至少15公斤的嗜酸性粒细胞性食管炎(EoE)儿童患者。 此外,Dupixent用于慢性阻塞性肺病(COPD)成人患者附加维持治疗的新适应症上市申请正在中美欧接受审查。患者群体的扩大将进一步助力Dupixent销售额的攀升。 Aubagio、Lemtrada两款药物被批准用于治疗多发性硬化...
Phase 3, double-blind, placebo-controlled trial evaluating the efficacy and safety of Dupixent in adults with uncontrolled, severe CPUO. During the 4-week run-in period, patients received a standard-of-care regimen comprised of a non-sedative...